P
Paula J. Lum
Researcher at University of California, San Francisco
Publications - 81
Citations - 3688
Paula J. Lum is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Hepatitis C & Buprenorphine. The author has an hindex of 29, co-authored 76 publications receiving 3279 citations. Previous affiliations of Paula J. Lum include San Francisco General Hospital & Johns Hopkins University School of Medicine.
Papers
More filters
Journal ArticleDOI
Hepatitis C Virus Seroconversion among Young Injection Drug Users: Relationships and Risks
Judith A. Hahn,Kimberly Page-Shafer,Paula J. Lum,Philippe Bourgois,Ellen Stein,Jennifer L. Evans,Michael P. Busch,Leslie H. Tobler,Bruce Phelps,Andrew R. Moss +9 more
TL;DR: Ubiquitous behaviors among young IDUs, such as the forming of injecting or sexual partnerships and consequent sharing of needles and drug preparation equipment, are risk factors for HCV.
Journal ArticleDOI
Gender differences in sexual and injection risk behavior among active young injection drug users in San Francisco (the UFO Study).
Jennifer L. Evans,Judith A. Hahn,Kimberly Page-Shafer,Paula J. Lum,Ellen Stein,Peter J. Davidson,Andrew R. Moss +6 more
TL;DR: In logistic regression models for borrowing a used needle and sharing drug preparation equipment, increased risk in females was explained by having an injection partner who was also a sexual partner, and injecting risk was greater in the young female compared to male IDUs despite equivalent frequency of injecting.
Journal ArticleDOI
Acute Hepatitis C Virus Infection in Young Adult Injection Drug Users: A Prospective Study of Incident Infection, Resolution, and Reinfection
Kimberly Page,Judith A. Hahn,Jennifer L. Evans,Stephen Shiboski,Paula J. Lum,Eric Delwart,Leslie H. Tobler,William Andrews,Lia Avanesyan,Stewart Cooper,Michael P. Busch,Michael P. Busch +11 more
TL;DR: In this large sample of young IDUs, females show demonstrative differences in their rates of viral clearance and kinetics of early viral decline, and reclearance suggest possible protection against persistent infection.
Journal ArticleDOI
HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study
Frederick L. Altice,R. Douglas Bruce,Gregory M. Lucas,Paula J. Lum,P. Todd Korthuis,Timothy P. Flanigan,Chinazo O. Cunningham,Lynn E. Sullivan,Pamela Vergara-Rodriguez,David A. Fiellin,Adan Cajina,Michael Botsko,Vijay Nandi,Marc N. Gourevitch,Ruth Finkelstein +14 more
TL;DR: Initiating BUP/NX in HIV clinical care settings is feasible and correlated with initiation of ART and improved CD4 lymphocyte counts, suggesting the need for multidisciplinary treatment strategies for this population of HIV-infected persons with opioid dependence.
Journal ArticleDOI
Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco.
Judith A. Hahn,Judith A. Hahn,Kimberly Page-Shafer,Paula J. Lum,Kristen C. Ochoa,Andrew R. Moss +5 more
TL;DR: It is concluded that anti‐HCV prevalence is lower than in previous studies of older IDUs, but 11% incidence implies high risk of HCV infection in a long injecting career.